• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Emergent BioSolutions

    Syngene

    Adare Pharma Solutions

    Quotient Sciences
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    Syngene

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Small Molecule API CDMO: A Capital Intensive Business?

    Exploring small molecule API market trends.

    Small Molecule API CDMO: A Capital Intensive Business?
    Small Molecule API CDMO: A Capital Intensive Business?
    Figure 1
    Small Molecule API CDMO: A Capital Intensive Business?
    Figure 2
    Small Molecule API CDMO: A Capital Intensive Business?
    Figure 3
    Small Molecule API CDMO: A Capital Intensive Business?
    Figure 4
    Small Molecule API CDMO: A Capital Intensive Business?
    Figure 5
    Dr. Michele Jermini and Dr. Enrico Polastro, Contributing Writers03.01.21
    For more than ten years now the pharmaceutical contract development and manufacturing organization (CDMO) industry has continued to attract the interest of financial investors, and to a lesser extent, industrial investors. This interest is reflected in a number of transactions where private equity houses have acquired various CDMOs, often paying hefty valuation multiples. Parallel to this trend, publicly quoted CDMOs have seen their stock prices reach new highs; corresponding to a total enterprise value (TEV), which is the sum of stock capitalization plus debt, north of twenty times EBITDA (earnings before interest, taxes and depreciation allowances).

    Several factors are behind this interest and high valuations among the investment community. These include expectations of continuing growth driven by megatrends such as a graying world population and advances in health care standards in emerging and developing countries that are poised to drive up pharmaceutical consumption. Other factors include the increasing trend toward outsourcing of development and manufacturing activities by pharmaceutical companies combined with opportunities to improve margins by consolidating the CDMO supply structure and optimizing operations implementing best practices learned from other industries.  

    Only time will tell whether or not these expectations will effectively materialize and justify the current valuation multiples. Obviously, there is no simple answer—investment requirements differ widely depending on the particular CDMI’s scope of activities and focus. However, past experience indicates that often financial investors and new entrants are surprised by the substantial capital expenditure (CapEx) outlays absorbed by the CDMO business. These swallow the better part of operating cash flows, resulting in modest, if not even negative, free cash generation levels. This situation often forces investors to revisit their financial plans with original CapEx projections proving to be inadequately low for effectively supporting growth targets.

    This is particularly the case for Western CDMOs focused on small molecule drug substance and active pharmaceutical ingredient (API) synthesis. A recent study sponsored by Aschimfarma—the Italian association of API producers1—and the Arthur D. Little yearly Round Robin covering sixteen Western small molecule API CDMOs with a combined turnover in excess of USD$3,000 million, yearly investment outlays committed by the sector have tended to increase over the years and are now corresponding to approximatively 11% of sales (see Figure 1). Comparable figures being noted amongst Indian API CDMOs.


    Figure 1

    To understand what average yearly CapEx outlay of 11% of sales mean, it is important to assess this figure within the broader context of the CDMO financial performance. Based on the Round Robin results—yearly investments correspond to almost 60% of the EBITDA generated—on average around a little less than 20% of sales. This means that after deducting variations in working capital, interest charges and taxes only modest free cash flows corresponding to approximatively 3% of sales are left for repaying debt or for rewarding shareholders through dividends (see Figure 2).


    Figure 2

    A look at the split of yearly investments committed by API CDMOs shows that on average about 50% of these are devoted to maintenance and compliance—be it regulatory or EHS (Environmental, Health & Safety) related. Little, if any, room for maneuver exists for cutting this type of investment without severely undermining and mortgaging the very survival and continuity of the business.

    Only the remaining half of investment outlays can be considered as discretionary being associated with growth initiatives such as capacity expansions or securing access to new capabilities.

    CapEx outlays differ widely between the various CDMOs surveyed, ranging between a low of 4.2% of sales to a high in excess of 25% of turnover. This reflects factors such as ownership structure, growth ambitions and conditions of the assets. A closer analysis shows a convergence in terms of the type of investments undertaken by small molecule API CDMOs and some common recurring themes emerge.
    As illustrated in Figure 3 these include: adapting the production infrastructure; beefing up process development capabilities; securing access to high containment synthesis capacity; developing capabilities in physical processing/particle engineering; reinforcing presence in main geographical areas of focus; and exploring the potential of continuous processes. Some larger players are devoting investments to expand their scope of activities to the drug product/formulated drug form (FdF) and biopharmaceuticals.


    Figure 3

    The driver behind these investments is the imperative for CDMOs to adapt their offerings and capabilities to the evolving requirements of pharmaceutical companies and the expectations vested by these in their drug substance suppliers. These reflect, among other factors, changes in the types and number of products entering development or reaching the market, accelerating time to market/product development cycles and the decreasing role played by Big Pharma as sources of NME (new molecular entities) innovation (see Figure 4).


    Figure 4

    In this new environment, CDMOs have to adapt their production capacity. Rather than on large volume vessels and dedicated units, the focus of investments is on flexible synthesis capacity comprising a larger number of smaller volume reactors structured as trains with readily reconfigurable interconnections. Such a design reflects the evolution noted in terms of number, diversity, structures and volumes of small molecule APIs being developed or reaching the market.

    Within this frame, it is important to note that the massive displacement of small molecule API by biopharmaceuticals predicted by some industry observers with the advent of the first recombinant products and Mab (monoclonal antibodies) has failed to occur. The latter continue to represent the backbone of the pharmaceutical industry accounting for about 75% of total sales and more than 60% of all NME approved by the FDA over the last ten years.

    While the dominance of small molecule API remains unchallenged, major developments and changes have occurred in terms of the type of molecules reaching the market, which has affected CDMO suppliers. These changes include the increasing complexity of molecular structures as reflected in their higher molecular weights and larger number of chiral centers.

    Parallel to this, volume requirements of APIs are decreasing—yearly tonnages exceeding the 10-ton threshold are increasingly becoming the exception—a development driven by the combination of higher potency and smaller patient pools targeted by the new drugs being developed or reaching the market.

    These drugs are increasingly addressing “specialist” indications including orphan diseases or patients carrying selected genetic markers, a development often referred to as the advent of “personalized medicine.” According to the Personalized Medicine Coalition (PMC), about 50% of the NME approved by the FDA during the last five years have corresponded to personalized drugs.2 This is illustrated by the number of “ib” drugs in advanced development or on the market. Each of these products are most often specific to selected genetic markers and cancer types. The resistance issues to a given drug often observed in cancer patients after a few months of treatment provide an additional boost to the proliferation of these types of products to extend treatment options.

    The increasing R&D focus of pharmaceutical companies on orphan indications and diseases characterized by substantial unmet therapeutic needs also results in accelerated development and registration timelines—fast track approval procedures are increasingly becoming the rule.

    Similarly, the share of NME developed by startups and emerging pharma as opposed to large established pharmaceutical companies is continuing to exceed 50%.

    These developments are having far reaching implications for small molecule API CDMOs. As volumes tend to decrease, new molecules continue to involve a growing diversity of chemotypes—each often invariably requiring in their synthesis different chemistries. As a result, development timelines are accelerating—vendors must adapt their capabilities and offerings accordingly.

    This includes having access to smaller-scale capacity suitably designed for optimal flexibility and the ability to swiftly accommodate a wide range of different reactions and products with minimal, if any, adaptations. Such flexibility obviously comes at a cost given the features that need to be incorporated in the new capacity design in order to allow for a wide range of situations and contingencies. This includes a larger number of vessels consisting of different construction material, downstream and ancillary equipment.

    Similarly, another must for CDMOs is to be able to support this capacity with adequate process development muscle. The synthesis procedures and technology packages provided by customers are rarely robust or reliable enough to be applied at more than the gram/laboratory scale. This reflects the limited process development work undertaken by the pharmaceutical originator because of either the lack of their own in-house resources or faster than expected product time to market following, for example, fast tracking of the drug by the FDA.

    Another consequence of shorter development timelines is the limited data often existing on the potency and associated industrial hygiene profile of API in the development pipeline and their intermediates. To mitigate potential risks and avoid potential liabilities, the precautionary principle is becoming the rule among most pharmaceutical companies. These are systematically requesting their API vendors to protect the work force and environment by performing the product synthesis in contained capacity.

    These requirements, combined with the increasing share of high potency API in the development pipeline or reaching the market, is behind the multiple investments undertaken by CDMOs in high containment—OEL 3 or higher—capacity. Contrary to the recent past, when capabilities alone helped CDMOs in securing a competitive edge, nowadays, CDMOs must have these capabilities just to be qualified by several pharmaceutical companies as a perspective supplier.

    The increasing complexity, size and weight of molecules being developed or reaching the market also has implications on their druggability—affecting aqueous solubility and intestinal membrane permeability with far reaching impacts on their pharmacokinetics, bioavailability and ease of formulation. Recent studies indicate that the share of “problematic of orally formulate” API given either poor water solubility or inadequate intestinal membrane permeability in the development pipeline now exceeds 70% (see Figure 5).


    Figure 5

    Various techniques, like milling, micronization or spray-drying—often referred to as “particle engineering or pre-formulation”—have been and continue to be developed to modify the API physico-chemical properties to facilitate its formulation, for example, by increasing its specific surface, reducing its particle size or making it amorphous disrupting the “native” crystal structure. In light of this, a number of API CDMOs have expanded their scope of activities to cover also the particle engineering step. Notable examples include Hovione and Lonza—the latter through the acquisition of Capsugel—Bend and subsequently Micromacinazione. Several other vendors followed suit albeit at a smaller scale.

    Another development behind the investments undertaken by API CDMOs is associated with the concerns among pharmaceutical companies on the sustainability and robustness of supply chains for their drug substance and related intermediate requirements, particularly when involving vendors in China and India.

    This is leading to a renewed interest in “near shoring” by developing Western supply sources that are viewed as more reliable and easier to monitor and deal with. Anticipating this re/near shoring by European and U.S. pharmaceutical companies, several Western API vendors are starting to plan major capacity expansions—Dottikon Exclusive Synthesis recently announced its intent to invest about $600 million as a notable example.3

    Parallel to this, other players like Dipharma, Flamma, Olon and Sterling Pharmaceuticals have moved for position securing access to process development and kilo/pilot scale capacity in the U.S., a key market for them. The intent being to reinforce their local presence and ability to serve U.S. customers—a substantial share of these often include startups and emerging pharmaceutical companies requiring more frequent interactions and hand-holding support compared to large pharma.

    Several CDMOs are also devoting increasing attention and resources to continuous processes. If commercial scale applications in API synthesis remain limited, the wider adoption of continuous processes is viewed as having the potential to disrupt the industry by making obsolete traditional batch equipment. This would lead to a redefinition of investment requirements and changing production economics while shortening cycle times.

    The focus of CDMO investments in continuous processes is mostly on demonstration scale equipment and in developing expertise on selected products. The idea being to prepare for the future once these techniques become an integral part of synthesis route and process design routines applied by pharmaceutical companies for their development products.

    Similar jockeying for positioning among CDMOs can also be noted in the investments undertaken by various players seeking to expand their scope of activities beyond just small molecule API synthesis. For example, larger players like Lonza, and to a lesser extent Novasep, for example, have established themselves as full-fledged CDMOs for both small molecule API and biopharmaceuticals. Other smaller players are actively developing capabilities in areas lying at the interface between small molecules and biopharmaceuticals.

    Here too these moves are prompted by the increasing number of ADC, oligonucleotides and peptides entering development and reaching the market, creating new opportunities for vendors but also introducing new requirements for successful participation. Investments undertaken by API CDMOs also include the investments either through organic development or acquisitions of some players like Cambrex, Carbogen, Lonza or Novasep in the area of drug product/FdF development and manufacturing services.

    The underlying rationale for the vendor is to offer to pharmaceutical customers an alternative to their own in-house production for both the drug substance and the drug product by outsourcing to a single vendor the entire supply chain. Such a setup is claimed by proponents to allow for compressing total sourcing costs, reducing lead times and eliminating sources of errors. Such a view is hotly disputed by opponents stressing the risk of relying on a single supplier for the entire supply chain. This divergence of opinions is also reflected by the different paths observed by the Cambrex and Lonza stock following their acquisition announcements of Halopharma and Capsugel-Bend, respectively.

    The first has seen its stock price sharply fall with 50% of the company market capitalization evaporating, eventually prompting private equity investors to take the company private. On the contrary, Lonza has seen its valuation multiples more than treble following the Capsugel deal. While other factors may have played a role, such as, for Cambrex, fears of reduced orders by Gilead, which at that time accounted for more than 30% of the company turnover, investor reactions most probably reflect their skepticism on the value creation potential for Cambrex to move in FdF. 

    References
    1. Indagine sul comparto dei principi attivi e degli intermedi per l’industria farmacutica – Ferderchimica – Aschimfarma November 2020
    2. The Personalized Medicine Report 2019 – Personalized Medicine Coalition
    3. Dottikon set to boost drug ingredient output – C&EN November 3, 2020


    Dr. Michele Jermini is the Managing Director of Alfa Chemicals (Suisse) SA mjermini@alfachemicalsint.com.

    Dr. Enrico Polastro is a Vice-President of Arthur D. Little polastro.enrico@adlittle.

    Related Features

    • R&D
      Small Innovators & Niche CROs

      Small Innovators & Niche CROs

      Smaller CROs have the opportunity to provide a niche approach to its clients, particularly smaller sponsors who have shared synergies.
      Neil Goodman, David Bruce and Mohamed El Malt, Europital 04.01.21

    • Laboratory Testing
      Focus on Science

      Focus on Science

      How to maximize lab performance and value through comprehensive equipment management.
      Rohit Shroff, Senior Vice President, Global Lab Products, Avantor 04.01.21

    • Analytical Services | Bioanalytical Services | Laboratory Testing | R&D
      Rapid and Data Rich Chromatographic Method Development

      Rapid and Data Rich Chromatographic Method Development

      An overview of what to consider when developing chromatographic methods.
      Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina 04.01.21


    • Preparing Your Post Pandemic Talent Strategy

      Preparing Your Post Pandemic Talent Strategy

      Areas for consideration for adopting the right approach to reinforce investments, optimize business and maximize your workforce.
      Neil Kelly, Managing Partner, Vector Partners 04.01.21

    • Laboratory Testing | R&D
      How Modern Near-Infrared Came to Be

      How Modern Near-Infrared Came to Be

      First region outside the visible to be discovered and last to be utilized.
      Gary E. Ritchie, Contributing Writer 04.01.21

    • APIs | Supply Chain
      Securing Your API Supply Chain: Three Keys to Success

      Securing Your API Supply Chain: Three Keys to Success

      Key considerations when outsourcing API procurement and supply chain management.
      Selwyn Lustman and Lina Cogan, LGM Pharma 04.01.21


    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Ensuring Pharma Manufacturing Quality
    • Bristol Myers Squibb Expands At Cambridge Crossing
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Amgen Completes Five Prime Acquisition
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login